Contact: Michael Muin
University of Missouri School of Medicine
Caption: MU scientist Tzyh-Chang Hwang, Ph.D., and colleagues have redefined a key regulatory process in the defective protein responsible for cystic fibrosis, which could change treatment for patients with the lethal genetic disease. Described in the current issue of the Proceedings of the National Academy of Sciences, Hwang's research could reveal a way to improve the effectiveness of the first drug that targets the underlying cause of cystic fibrosis.
Credit: University of Missouri School of Medicine
Usage Restrictions: None
Related news release: Discovery could increase efficacy of promising cystic fibrosis drug